Clinigen Group PLC takes back direct control of two of its oncology drugs in the US #Sales @MondoPlayer [Video]

Cristian WorthingtonCristian Worthington Twitter, FeedToPost

To see the original post and the Video, click here

Specialty pharma Clinigen Group PLC (LON:CLIN) has taken back direct control of its Ethyol and Totect oncology drugs from Cumberland Pharmaceuticals. The two drugs are prescribed by doctors to help reduce the toxic effects of chemotherapy and radiation. READ: Clinigen completes acquisition of US...

Watch/Read More

Specialty pharma Clinigen Group PLC (LON:CLIN) has taken back direct control of its Ethyol and Totect oncology drugs from Cumberland Pharmaceuticals.

The two drugs are prescribed by doctors to help reduce the toxic effects of chemotherapy and radiation.

READ: Clinigen completes acquisition of US Proleukin rights

Clinigen and Cumberland entered into a strategic partnership back in 2015, and the latter was subsequently awarded the exclusive rights to market and distribute Ethyol …

Tom-H.jpg